218 related articles for article (PubMed ID: 15681831)
1. A multidisciplinary evaluation of the effectiveness of cyclosporine a in dystrophic mdx mice.
De Luca A; Nico B; Liantonio A; Didonna MP; Fraysse B; Pierno S; Burdi R; Mangieri D; Rolland JF; Camerino C; Zallone A; Confalonieri P; Andreetta F; Arnoldi E; Courdier-Fruh I; Magyar JP; Frigeri A; Pisoni M; Svelto M; Conte Camerino D
Am J Pathol; 2005 Feb; 166(2):477-89. PubMed ID: 15681831
[TBL] [Abstract][Full Text] [Related]
2. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1.
De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Fraysse B; Mirabella M; Servidei S; Rüegg UT; Conte Camerino D
J Pharmacol Exp Ther; 2003 Jan; 304(1):453-63. PubMed ID: 12490622
[TBL] [Abstract][Full Text] [Related]
3. First evaluation of the potential effectiveness in muscular dystrophy of a novel chimeric compound, BN 82270, acting as calpain-inhibitor and anti-oxidant.
Burdi R; Didonna MP; Pignol B; Nico B; Mangieri D; Rolland JF; Camerino C; Zallone A; Ferro P; Andreetta F; Confalonieri P; De Luca A
Neuromuscul Disord; 2006 Apr; 16(4):237-48. PubMed ID: 16542837
[TBL] [Abstract][Full Text] [Related]
4. Role of tumour necrosis factor alpha, but not of cyclo-oxygenase-2-derived eicosanoids, on functional and morphological indices of dystrophic progression in mdx mice: a pharmacological approach.
Pierno S; Nico B; Burdi R; Liantonio A; Didonna MP; Cippone V; Fraysse B; Rolland JF; Mangieri D; Andreetta F; Ferro P; Camerino C; Zallone A; Confalonieri P; De Luca A
Neuropathol Appl Neurobiol; 2007 Jun; 33(3):344-59. PubMed ID: 17493014
[TBL] [Abstract][Full Text] [Related]
5. Multiple pathological events in exercised dystrophic mdx mice are targeted by pentoxifylline: outcome of a large array of in vivo and ex vivo tests.
Burdi R; Rolland JF; Fraysse B; Litvinova K; Cozzoli A; Giannuzzi V; Liantonio A; Camerino GM; Sblendorio V; Capogrosso RF; Palmieri B; Andreetta F; Confalonieri P; De Benedictis L; Montagnani M; De Luca A
J Appl Physiol (1985); 2009 Apr; 106(4):1311-24. PubMed ID: 19131478
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of the angiotensin-converting enzyme decreases skeletal muscle fibrosis in dystrophic mice by a diminution in the expression and activity of connective tissue growth factor (CTGF/CCN-2).
Morales MG; Cabrera D; Céspedes C; Vio CP; Vazquez Y; Brandan E; Cabello-Verrugio C
Cell Tissue Res; 2013 Jul; 353(1):173-87. PubMed ID: 23673415
[TBL] [Abstract][Full Text] [Related]
7. Contractile efficiency of dystrophic mdx mouse muscle: in vivo and ex vivo assessment of adaptation to exercise of functional end points.
Capogrosso RF; Mantuano P; Cozzoli A; Sanarica F; Massari AM; Conte E; Fonzino A; Giustino A; Rolland JF; Quaranta A; De Bellis M; Camerino GM; Grange RW; De Luca A
J Appl Physiol (1985); 2017 Apr; 122(4):828-843. PubMed ID: 28057817
[TBL] [Abstract][Full Text] [Related]
8. Prevention of muscle fibrosis and myonecrosis in mdx mice by suramin, a TGF-β1 blocker.
Taniguti AP; Pertille A; Matsumura CY; Santo Neto H; Marques MJ
Muscle Nerve; 2011 Jan; 43(1):82-7. PubMed ID: 21108244
[TBL] [Abstract][Full Text] [Related]
9. Nuclear factor kappa-B blockade reduces skeletal muscle degeneration and enhances muscle function in Mdx mice.
Messina S; Bitto A; Aguennouz M; Minutoli L; Monici MC; Altavilla D; Squadrito F; Vita G
Exp Neurol; 2006 Mar; 198(1):234-41. PubMed ID: 16410003
[TBL] [Abstract][Full Text] [Related]
10. The calcineurin signal transduction pathway is essential for successful muscle regeneration in mdx dystrophic mice.
Stupka N; Gregorevic P; Plant DR; Lynch GS
Acta Neuropathol; 2004 Apr; 107(4):299-310. PubMed ID: 14727129
[TBL] [Abstract][Full Text] [Related]
11. Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle.
De Luca A; Nico B; Rolland JF; Cozzoli A; Burdi R; Mangieri D; Giannuzzi V; Liantonio A; Cippone V; De Bellis M; Nicchia GP; Camerino GM; Frigeri A; Svelto M; Camerino DC
Neurobiol Dis; 2008 Nov; 32(2):243-53. PubMed ID: 18694830
[TBL] [Abstract][Full Text] [Related]
12. Insulin-like growth factor-I analogue protects muscles of dystrophic mdx mice from contraction-mediated damage.
Gehrig SM; Ryall JG; Schertzer JD; Lynch GS
Exp Physiol; 2008 Nov; 93(11):1190-8. PubMed ID: 18567600
[TBL] [Abstract][Full Text] [Related]
13. Efficiency and functional consequences of adenovirus-mediated in vivo gene transfer to normal and dystrophic (mdx) mouse diaphragm.
Petrof BJ; Acsadi G; Jani A; Massie B; Bourdon J; Matusiewicz N; Yang L; Lochmüller H; Karpati G
Am J Respir Cell Mol Biol; 1995 Nov; 13(5):508-17. PubMed ID: 7576685
[TBL] [Abstract][Full Text] [Related]
14. Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine.
De Luca A; Pierno S; Liantonio A; Cetrone M; Camerino C; Simonetti S; Papadia F; Camerino DC
Br J Pharmacol; 2001 Mar; 132(5):1047-54. PubMed ID: 11226135
[TBL] [Abstract][Full Text] [Related]
15. Resveratrol ameliorates muscular pathology in the dystrophic mdx mouse, a model for Duchenne muscular dystrophy.
Hori YS; Kuno A; Hosoda R; Tanno M; Miura T; Shimamoto K; Horio Y
J Pharmacol Exp Ther; 2011 Sep; 338(3):784-94. PubMed ID: 21652783
[TBL] [Abstract][Full Text] [Related]
16. Functional improvement of dystrophic muscle by myostatin blockade.
Bogdanovich S; Krag TO; Barton ER; Morris LD; Whittemore LA; Ahima RS; Khurana TS
Nature; 2002 Nov; 420(6914):418-21. PubMed ID: 12459784
[TBL] [Abstract][Full Text] [Related]
17. Localization and early time course of TGF-beta 1 mRNA expression in dystrophic muscle.
Gosselin LE; Williams JE; Deering M; Brazeau D; Koury S; Martinez DA
Muscle Nerve; 2004 Nov; 30(5):645-53. PubMed ID: 15389721
[TBL] [Abstract][Full Text] [Related]
18. Diltiazem and verapamil protect dystrophin-deficient muscle fibers of MDX mice from degeneration: a potential role in calcium buffering and sarcolemmal stability.
Matsumura CY; Pertille A; Albuquerque TC; Santo Neto H; Marques MJ
Muscle Nerve; 2009 Feb; 39(2):167-76. PubMed ID: 19145649
[TBL] [Abstract][Full Text] [Related]
19. Effects of a CRF2R agonist and exercise on mdx and wildtype skeletal muscle.
Hall JE; Kaczor JJ; Hettinga BP; Isfort RJ; Tarnopolsky MA
Muscle Nerve; 2007 Sep; 36(3):336-41. PubMed ID: 17503504
[TBL] [Abstract][Full Text] [Related]
20. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy.
Cozzoli A; Capogrosso RF; Sblendorio VT; Dinardo MM; Jagerschmidt C; Namour F; Camerino GM; De Luca A
Pharmacol Res; 2013 Jun; 72():9-24. PubMed ID: 23523664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
